BioNTech SE: all 124 studies
Page 2 of 2. Open to participants first (33), then studies with results posted, then the rest; newest registration first within each.
- Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy PopulationCompletedNCT04649021Phase 2
- A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced MelanomaTerminatedNCT04625205Phase 1
- A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1Active, not recruitingNCT04534205Phase 2/3
- A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ TumorsActive, not recruitingNCT04503278Phase 1
- A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal CancerActive, not recruitingNCT04486378Phase 2
- A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced MelanomaTerminatedNCT03597282Phase 1
- A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung CancerCompletedNCT03380871Phase 1
- Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACCStatus unknownNCT03291002Phase 1
- Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as RadioimmunotherapyTerminatedNCT03118349Phase 1
- A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder CancerCompletedNCT02897765Phase 1
- Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1TerminatedNCT02687230Phase 1
- Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive MalignanciesTerminatedNCT02672917Phase 1
- Re-Examination of Tumor Material and Re-Evaluation of Patient Data From Patients Treated With Neo-adjuvant TherapyCompletedNCT02449993
- Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced MelanomaCompletedNCT02410733Phase 1
- RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uIDCompletedNCT02316457Phase 1
- RNActive® Rabies Vaccine (CV7201) in Healthy AdultsCompletedNCT02241135Phase 1
- Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy AdultsCompletedNCT02238756Phase 1
- An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate Risk Patients With Prostate CancerTerminatedNCT02140138Phase 2
- IVAC MUTANOME Phase I Clinical TrialCompletedNCT02035956Phase 1
- Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC)TerminatedNCT01915524Phase 1
- Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate CancerTerminatedNCT01817738Phase 1/2
- RBL001/RBL002 Phase I Clinical TrialCompletedNCT01684241Phase 1
- Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)CompletedNCT00923312Phase 1/2
- Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory DiseaseCompletedNCT00831467Phase 1/2